Cefdinir in respiratory tract infections

Yoichi Nakanishi, Osamu Katoh, Kenya Hiura, Tsuneko Yamaguchi, Shigetaka Kuroki, Yousuke Aoki, Hozumi Yamada

Research output: Contribution to journalArticlepeer-review


We performed a clinical study on cefdinir (CFDN), a new cephem antibiotic with a wide spectrum of antibacterial activity, and obtained the following results. 1. Serum and sputum levels of CFDN CFDN was given orally in a dose of 100 or 200mg t. i. d. for 7 consecutive days. The serum was collected 1 h and the sputum 4 h after administration. The average serum level was 0.56μg/ml in 8 patients. Sputum levels were detectable in 5 of the 8 patients and averaged 0.03μg/ml. 2. Clinical effects The clinical effect of CFDN were evaluated in 14 patients with respiratory tract infections: 5 with acute exacerbation of chronic bronchitis, 5 with acute exacerbation of bronchiectasis, 3 with acute bronchitis and 1 with pneumonia. The overall efficacy rate was 71.4%(10/14). Pathogenic bacteria were completely eradicated in 5 of 9 patients (55.6%). In one patient mild hypertransaminasemia wasseen, but this disappeared at the end of administration.

Original languageEnglish
Pages (from-to)560-564
Number of pages5
Publication statusPublished - 1989
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Cefdinir in respiratory tract infections'. Together they form a unique fingerprint.

Cite this